A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer

NCT ID: NCT04147806

Last Updated: 2024-06-11

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-08-01
• Study Completion Date: 2026-07-13

Brief Summary

The present study evaluates clinical outcomes and treatment-related toxicity following definitive ultra-high dose external beam radiotherapy delivered with two different regimens in patients with intermediate-risk adenocarcinoma of the prostate. Modern computer-driven technology enables the implementation of ultra-high hypofractionated Image-Guided Radiotherapy (IGRT) safely.

Prostate cancer patients classified according to the current National Comprehensive Cancer Network (NCCN) guidelines as intermediate risk (biopsy Gleason score of 7 and/or Prostate Specific Antigen (PSA) level >10 and ≤20 ng/mL and/or Stage T1, T2a, T2b or T2c) are eligible for this study.

Patients will undergo IGRT with volumetric intensity-modulated arc radiotherapy (VMAT) with state-of-the-art treatment-planning and quality assurance procedures. Emphasis is placed on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility, while a urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking. Previously untreated patients with intermediate-risk prostate cancer will be prospectively randomized to receive either 45 Gy in five fractions of 9 Gy each vs. 24 Gy in a single-dose.

Patients will be followed at one month post-treatment and every 3 months for up to 12 months (+/- 4 weeks) and every 6 months thereafter. Acute and chronic toxicity evaluations will focus on urinary, rectal and sexual functions and will be assessed through validated questionnaires. Serum PSA values will be regularly acquired during follow-up. A multiparametric MRI will be performed at baseline, 6, 12 and 24 months following intervention. Additionally, a post-treatment diffusion-weighted MRI (DW-MRI) will be performed within 15 minutes of the first treatment, to measure early physiologic changes, such as perfusion and ischemia, that may correlate with clinically relevant end-points. Post-treatment prostate needle biopsies will be obtained at 24 months to evaluate pathologic response to therapy. The study will be continuously monitored for a minimum of 5 years. In the event unexpected severe (grade ≥3) toxicities are observed in any one of the treatment arms, the study will be terminated according to the stopping rule >3/first 15 patients.

Detailed Description

This is open label feasibility study where patients enrolled in the study will undergo image-guided, intensity-modulated radiotherapy using the same equipment, techniques, and treatment-planning procedures as currently practiced at CCU. Eligible patients will receive either 45 Gy in 5 sessions each of 9 Gy delivered in one week (arm A) or 24 Gy in 1 session (arm B) to assess the dose limiting toxicities in the two groups. Patients will be randomized to arm A or arm B.

Dose limiting toxicity (DLT) is defined as any Grade 3 urinary or rectal toxicity, based on NCI CTCAE v4.0, observed within 3 months of completion of protocol radiation. If, at any point in the conduct of the trial, DLTs are observed in three patients in a study arm, accrual to that arm will be terminated.

There are three aspects of this study that will be different from the currently used standard treatment for definitive external beam treatment of prostate cancer:

1. The dose-fractionation scheme, as per the treatment arm.

2. Acquisition of a set of prostate biopsies at 24 months post treatment

3. Examination of imaging response based on multi-parametric MRI

Conditions

Prostate Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

IGRT 45 Gy in 5 fractions of 9 Gy

Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days

Group Type: ACTIVE_COMPARATOR

IGRT 45 Gy in 5 fractions of 9 Gy

Intervention Type: RADIATION

Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation

IGRT 24 Gy single dose

Intervention Type: RADIATION

Administration of a single dose of 24 Gy in one session

Dexamethasone

Intervention Type: DRUG

4 mg by mouth on treatment days only

Tamsulosin

Intervention Type: DRUG

0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.

IGRT 24 Gy single dose

single fraction IGRT at a prescription dose of 24 Gy

Group Type: EXPERIMENTAL

IGRT 45 Gy in 5 fractions of 9 Gy

Intervention Type: RADIATION

Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation

IGRT 24 Gy single dose

Intervention Type: RADIATION

Administration of a single dose of 24 Gy in one session

Dexamethasone

Intervention Type: DRUG

4 mg by mouth on treatment days only

Tamsulosin

Intervention Type: DRUG

0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.

Interventions

IGRT 45 Gy in 5 fractions of 9 Gy

Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation

Intervention Type: RADIATION

IGRT 24 Gy single dose

Administration of a single dose of 24 Gy in one session

Intervention Type: RADIATION

Dexamethasone

4 mg by mouth on treatment days only

Intervention Type: DRUG

Tamsulosin

0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.

Intervention Type: DRUG

Other Intervention Names

Dexasone; Flomax Relief

Eligibility Criteria

Inclusion Criteria

• Signed study specific informed consent form;
• Histologic confirmation of adenocarcinoma of the prostate by biopsy;
• PSA ≤ 20 ng/mL;
• Gleason score 7;
• Staging MRI must confirm American Joint Committee on Cancer (AJCC) stage T1, T2a, T2b or T2c;
• No direct evidence of regional or distant metastases after appropriate staging studies;
• Age ≥ 50;
• Performance Status 0-2;
• Internation Prostate Symptom Score score must be ≤ 15 (alpha blockers allowed);
• CT scan or Ultrasound-based volume estimation of prostate gland ≤ 100 grams;

Exclusion Criteria

• Positive lymph-nodes or metastatic disease from prostate cancer on imaging studies
• Prior invasive malignancy unless disease-free for a minimum of 5 years
• Tumour Clinical stage T3 or T4 on MRI
• PSA > 20 ng/mL
• Gleason score > 7
• Previous pelvic radiotherapy
• Previous surgery for prostate cancer
• Previous transurethral resection of the prostate (TURP)
• History of Crohn's Disease or Ulcerative Colitis
• Previous significant urinary obstructive symptoms
• Significant psychiatric illness
• Ultrasound or CT estimate of prostate volume > 100 grams
• Severe, active co-morbidity

• Minimum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Albert Einstein College of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Madhur Garg, MD

Role: PRINCIPAL_INVESTIGATOR

Associate Clinical Director

Locations

Montefiore Medical Center - Moses Campus

The Bronx, New York, United States

Countries

United States

Other Identifiers

2016-6545

Identifier Type: -

Identifier Source: org_study_id